Molecular biomarkers, such as point mutations and epigenetic and proteomic profiles, play a crucial role in risk prediction, diagnosis, and prognosis in acute myeloid leukemia patients.
Prada-Arismendy, J., Arroyave, J., & Röthlisberger, S. (2017). Molecular biomarkers in acute myeloid leukemia.. Blood reviews, 31 1, 63-76 . https://doi.org/10.1016/j.blre.2016.08.005.
